Age, Biography and Wiki

Miriam Merad was born on 1969 in Paris, France, is an Algerian professor (born 1969). Discover Miriam Merad's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is she in this year and how she spends money? Also learn how she earned most of networth at the age of 55 years old?

Popular As N/A
Occupation N/A
Age 55 years old
Zodiac Sign N/A
Born 1969
Birthday
Birthplace Paris, France
Nationality France

We recommend you to check the complete list of Famous People born on . She is a member of famous professor with the age 55 years old group.

Miriam Merad Height, Weight & Measurements

At 55 years old, Miriam Merad height not available right now. We will update Miriam Merad's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.

Physical Status
Height Not Available
Weight Not Available
Body Measurements Not Available
Eye Color Not Available
Hair Color Not Available

Dating & Relationship status

She is currently single. She is not dating anyone. We don't have much information about She's past relationship and any previous engaged. According to our Database, She has no children.

Family
Parents Not Available
Husband Not Available
Sibling Not Available
Children Not Available

Miriam Merad Net Worth

Her net worth has been growing significantly in 2023-2024. So, how much is Miriam Merad worth at the age of 55 years old? Miriam Merad’s income source is mostly from being a successful professor. She is from France. We have estimated Miriam Merad's net worth, money, salary, income, and assets.

Net Worth in 2024 $1 Million - $5 Million
Salary in 2024 Under Review
Net Worth in 2023 Pending
Salary in 2023 Under Review
House Not Available
Cars Not Available
Source of Income professor

Miriam Merad Social Network

Instagram
Linkedin
Twitter Miriam Merad Twitter
Facebook
Wikipedia Miriam Merad Wikipedia
Imdb

Timeline

1969

Miram Merad (born 1969) is a French-Algerian professor in Cancer immunology and the Director of the Marc and Jennifer Lipschultz Precision Immunology Institute (PrIISM) at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York, NY.

1985

Miriam Merad received her M.D. from the medical school at the University of Algiers in 1985 and completed her residency in hematology and oncology at the Paris Diderot University.

After obtaining a Master's degree in Biotechnology from the Paris Diderot University, she moved to Stanford University to perform a PhD in the laboratory of Edgar Engleman.

Merad’s clinical training in Hematology / Oncology and bone marrow transplantation in the Hôpital Saint-Louis and Institut Gustave Roussy in Paris shaped her initial interest in immunotherapy and inspired her move to Stanford to study dendritic cell-based vaccines with Engleman.

Realizing that very little was known about myeloid cell development, Merad collaborated with Irving Weissman at Stanford, who provided her with the tools to study the origin of macrophages and dendritic cells.

Merad's collaboration with Weissman resulted in a series of ontogeny studies that led to the re-writing of textbook chapters describing the origin of macrophages and dendritic cells.

2004

She was first recruited to the ISMMS in 2004 and promoted to the rank of associate professor with Tenure in 2007 and to Full Professor in 2010.

2014

She obtained an Endowed Chair in Cancer Immunology in 2014.

2016

In 2016, Merad was appointed Director of the Immunology Institute at ISMMS, which had been founded by Lloyd Mayer and Sergio A. Lira in 2007.

The institute was renamed the Precision Immunology Institute (PrIISM) to reflect Merad's vision of transforming the institute to encompass a new, dedicated focus on human immunology and accelerating the translation of research advances made in foundational immunology in preclinical models into new therapeutic approaches.

Under Merad's leadership, PrIISM has launched and co-founded with other ISMMS institutes, many programs and centers that support highly productive collaborations between physicians and scientists and enhance synergy between fundamental, translational and clinical research initiatives.

These centers and programs include the Human Immune Monitoring Center, the Microbiome Translational Center, the Center for Inborn Errors of Immunity, the TARGET and INTERACT programs and the Center for Computational Immunology.

In August 2023, Merad became the founding Chair of the Department of Immunology and Immunotherapy (DII), a new research department launched at Icahn Mount Sinai that intends to foster a comprehensive understanding of the fundamental biology and profound impact of the immune system on human health and disease.

The DII aims to empower researchers to explore groundbreaking scientific inquiries about the immune system and develop innovative types of immunotherapy.

Miram Merad's early studies were among the first to identify the mechanisms that control the development and functional identity of tissue resident dendritic cells and macrophages.

In particular, her laboratory established the embryonic origin of tissue resident macrophages, microglia and Langerhans cells and investigates their distinct contributions to health and disease.

These studies have revealed the critical contribution of tissue resident macrophages to organ physiology including synaptic pruning, gut peristaltism, fat metabolism and vascular integrity.

The Merad laboratory identified a new subset of dendritic cells, the tissue resident CD103+ DC lineage, that are specialized in anti-viral and anti-tumor immunity.

Understanding how different myeloid cell subsets drive distinct inflammatory diseases is one focus of the Merad group's research.

In 2021, they identified how mutations in mitogen-activated protein kinase pathway genes trigger sensescence in multipotent human hematopoietic progenitor cells that cause multisystem Langerhans Cell Histiocytosis disease by skewing progenitor differentiation towards the mononuclear phagocyte lineage.

In 2022, they reported that severe COVID19 disease was associated with a reduction in the tissue-resident lung alveolar macrophages that control tissue repair and an increase in inflammatory monocytes and monocyte-derived macrophages.

The Merad lab has made many discoveries demonstrating the roles that dendritic cells and macrophages play within the tumor microenvironment.

The two distinct lineages of macrophages that Merad defined are represented in tumors, with the different developmental origins dictating their specific roles in shaping the tumor microenvironment.

In human lung tumors, Merad's team found that tissue-resident macrophages gather near to tumour cells early in tumour formation and make the tumour cells more invasive, and they also activate a regulatory T cell response that protects the tumour cells from the immune system.

During tumor growth, the tissue-resident macrophages move to the periphery and monocyte-derived macrophages dominate the tumor-microenvironment.

Other recent key advances from the Merad team in this area include the identification of TREM2 tumor macrophages as immunosuppressive cells that limit natural killer cell recruitment and activity in a murine model of lung adenocarcinoma, the characterization of mature dendritic cells enriched in immunoregulatory molecules (mregDCs) that limit responses to immune checkpoint blockade, and the niches in tumors in which mregDCs operate.

The Merad lab generates detailed transcriptional and epigenetic atlases of dendritic cells and macrophages that are available as resources to uncover new insights into the regulatory networks and molecular identity of these myeloid cells.

In addition to her research program, Merad has published articles on new approaches to cancer immunotherapy clinical trials, how Long COVID can be classified, the importance of immigrants to science in the US and written about her experiences as a mother and a scientist.

2018

She is the corecipient of the 2018 William B. Coley Award for Distinguished Research in Basic Immunology and a member of the United States National Academy of Sciences and the National Academy of Medicine.